Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular ...
REHOVOT, Israel and BRIDGEWATER, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical …